Industry news
The Medicines Company sells three drugs (Recothrom, Preveleak and Raplixa) to Mallinckrodt
The Medicines Company announced that it has entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt will acquire The Medicines Company's global portfolio of three haemostasis products – Recothrom Thrombin topical (recombinant), PreveLeak, and Raplixa (fibrin sealant). The transaction is expected to close in the first calendar quarter of 2016.